# JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

> **NCT05002270** · PHASE1,PHASE2 · COMPLETED · sponsor: **Jacobio Pharmaceuticals Co., Ltd.** · enrollment: 29 (actual)

## Conditions studied

- Advanced Solid Tumor
- NSCLC
- CRC

## Interventions

- **DRUG:** JAB-21822 (KRAS G12C inhibitor)
- **DRUG:** JAB-21822 (KRAS G12C inhibitor)
- **DRUG:** JAB-21822 (KRAS G12C inhibitor)
- **DRUG:** Cetuximab (EGFR inhibitor)

## Key facts

- **NCT ID:** NCT05002270
- **Lead sponsor:** Jacobio Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-03
- **Primary completion:** 2025-02-12
- **Final completion:** 2025-02-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05002270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05002270, "JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05002270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*